Skip to main content
. Author manuscript; available in PMC: 2020 Aug 24.
Published in final edited form as: ACS Infect Dis. 2015 Mar 30;1(5):186–197. doi: 10.1021/id5000426

Table 1.

Vaccines against Ebola Virus

Vaccine rAd5/ChAd3 rVSV/ΔG/GP EBOV
Replication potential Replication deficient Replication competent
Mechanism of protection CD8+ T cell mediated Antibody mediated
Booster requirement Modified vaccinia Ankara
Durability 10 months with booster vaccination in nonhuman primates 12-18 months in rodents
14 months in nonhuman primates (MARV)
Clinical trial Phase II/III Phase II/III